{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:37:28Z","timestamp":1761950248431,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"am","delay-in-days":311,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.resinv.2024.02.012","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T09:41:05Z","timestamp":1709890865000},"page":"388-394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glasgow prognostic score and body mass index predict short-term discontinuation of the antifibrotic agents pirfenidone and nintedanib"],"prefix":"10.1016","volume":"62","author":[{"given":"Kazutaka","family":"Takehara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4974-9026","authenticated-orcid":false,"given":"Yasuhiko","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8341-9381","authenticated-orcid":false,"given":"Yoshimasa","family":"Hachisu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuyoshi","family":"Utsugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seishi","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakiyo","family":"Yatomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0837-9329","authenticated-orcid":false,"given":"Hiroaki","family":"Tsurumaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Wakamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norimitsu","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazue","family":"Umetsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Kouno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5966-4579","authenticated-orcid":false,"given":"Noriaki","family":"Sunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Maeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3862-1887","authenticated-orcid":false,"given":"Takeshi","family":"Hisada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2024.02.012_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1513\/pats.200512-131TK","article-title":"Is idiopathic pulmonary fibrosis an environmental disease?","volume":"3","author":"Taskar","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.resinv.2024.02.012_bib2","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1038\/s41598-021-81591-z","article-title":"Occupational and environmental risk factors of idiopathic pulmonary fibrosis: a systematic review and meta-analyses","volume":"11","author":"Park","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.resinv.2024.02.012_bib3","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1021\/acs.estlett.1c00659","article-title":"Progression of idiopathic pulmonary fibrosis is associated with silica\/silicate inhalation","volume":"8","author":"Koga","year":"2021","journal-title":"Environ Sci Technol Lett"},{"key":"10.1016\/j.resinv.2024.02.012_bib4","first-page":"11","article-title":"Differential discontinuation profiles between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis","author":"Takehara","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.resinv.2024.02.012_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.resinv.2020.08.003","article-title":"Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis","volume":"59","author":"Uchida","year":"2021","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2024.02.012_bib6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/sj.bjc.6605855","article-title":"The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study","volume":"103","author":"Proctor","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.resinv.2024.02.012_bib7","article-title":"The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2024.02.012_bib8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejso.2016.10.015","article-title":"Preoperative Glasgow Prognostic Score as additional independent prognostic parameter for patients with esophageal cancer after curative esophagectomy","volume":"43","author":"Lindenmann","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.resinv.2024.02.012_bib9","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.21873\/anticanres.13262","article-title":"Post-treatment glasgow prognostic score predicts efficacy in advanced non-small-cell lung cancer treated with anti-PD1","volume":"39","author":"Kasahara","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.resinv.2024.02.012_bib10","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1111\/1759-7714.13526","article-title":"Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment","volume":"11","author":"Kasahara","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.resinv.2024.02.012_bib11","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.02.012_bib12","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.resinv.2024.02.012_bib13","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","article-title":"Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer","volume":"89","author":"Forrest","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.resinv.2024.02.012_bib14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.resinv.2024.02.012_bib15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.resinv.2024.02.012_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010096","article-title":"Treatment with tumor necrosis factor-alpha inhibitors, history of allergy, and hypercalcemia are risk factors of immune reconstitution inflammatory syndrome in HIV-negative pulmonary tuberculosis patients","volume":"9","author":"Hachisu","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2024.02.012_bib17","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.21037\/jtd-20-803","article-title":"Prognostic nutritional index as a predictor of mortality in nontuberculous mycobacterial lung disease","volume":"12","author":"Hachisu","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.resinv.2024.02.012_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2014.10.047","article-title":"Serial (1)(2)(3)I-metaiodobenzylguanidine imaging predicts the risk of sudden cardiac death in patients with chronic heart failure","volume":"179","author":"Kasama","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.resinv.2024.02.012_bib19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/resp.13184","article-title":"Prognostic significance of Glasgow prognostic score in patients with acute exacerbation of idiopathic pulmonary fibrosis","volume":"23","author":"Kang","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2024.02.012_bib20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.resinv.2023.02.010","article-title":"Skeletal muscle atrophy and short-term mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis: an observational cohort study","volume":"61","author":"Ito","year":"2023","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2024.02.012_bib21","first-page":"102","article-title":"Prognostic factors for idiopathic pulmonary fibrosis: clinical, physiologic, pathologic, and molecular aspects","volume":"28","author":"Lee","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.resinv.2024.02.012_bib22","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1378\/chest.08-0754","article-title":"Serum albumin concentration and waiting list mortality in idiopathic interstitial pneumonia","volume":"135","author":"Zisman","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2024.02.012_bib23","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1378\/chest.06-2784","article-title":"Body mass index and mortality in patients with idiopathic pulmonary fibrosis","volume":"131","author":"Alakhras","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2024.02.012_bib24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.resinv.2018.12.010","article-title":"Low starting-dosage of nintedanib for the reduction of early termination","volume":"57","author":"Ikeda","year":"2019","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2024.02.012_bib25","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.resinv.2021.01.002","article-title":"Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease","volume":"59","author":"Katano","year":"2021","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2024.02.012_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619872890","article-title":"Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study","volume":"13","author":"Oishi","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.resinv.2024.02.012_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00443-2021","article-title":"Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study","volume":"8","author":"Faverio","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2024.02.012_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nut.2018.12.008","article-title":"What are the best indicators to assess malnutrition in idiopathic pulmonary fibrosis patients? A cross-sectional study in a referral center","volume":"62","author":"Jouneau","year":"2019","journal-title":"Nutrition"},{"key":"10.1016\/j.resinv.2024.02.012_bib29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12890-019-0841-7","article-title":"Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis","volume":"19","author":"Ikeda","year":"2019","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2024.02.012_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12890-018-0575-y","article-title":"Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry","volume":"18","author":"Jo","year":"2018","journal-title":"BMC Pulm Med"},{"year":"2021","series-title":"What are the physical signs in the last weeks or days?","author":"Foundation","key":"10.1016\/j.resinv.2024.02.012_bib31"},{"key":"10.1016\/j.resinv.2024.02.012_bib32","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/resp.12941","article-title":"Fat-free mass index predicts survival in patients with idiopathic pulmonary fibrosis","volume":"22","author":"Nishiyama","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2024.02.012_bib33","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000490355","article-title":"The clinical significance of body weight loss in idiopathic pulmonary fibrosis patients","volume":"96","author":"Nakatsuka","year":"2018","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2024.02.012_bib34","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00418-2019","article-title":"Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity","volume":"53","author":"Jouneau","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.02.012_bib35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12931-020-01528-4","article-title":"Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis","volume":"21","author":"Jouneau","year":"2020","journal-title":"Respir Res"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524000376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524000376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:33:06Z","timestamp":1761949986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534524000376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2212534524000376"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2024.02.012","relation":{},"ISSN":["2212-5345"],"issn-type":[{"type":"print","value":"2212-5345"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glasgow prognostic score and body mass index predict short-term discontinuation of the antifibrotic agents pirfenidone and nintedanib","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2024.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}